Stephen Haworth
Chief Tech/Sci/R&D Officer chez XORTX THERAPEUTICS INC.
Fortune : - $ au 31/03/2024
Profil
Stephen Haworth is currently the Chief Medical Officer at XORTX Therapeutics, Inc. He previously worked as the Executive Director-Medical at CorMedix, Inc. from 2017 to 2018, and as the Chief Medical Officer & Vice President at Elusys Therapeutics, Inc. from 2012 to 2013.
He also served as the Vice President at VaxInnate Corp.
from 2015 to 2016.
Haworth received his undergraduate degree from University College London and his doctorate from UCL Medical School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
XORTX THERAPEUTICS, INC.
-.--% | 04/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Stephen Haworth
| Sociétés | Poste | Début |
|---|---|---|
| XORTX THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 01/07/2021 |
Anciens postes connus de Stephen Haworth
| Sociétés | Poste | Fin |
|---|---|---|
| CORMEDIX INC. | Chief Tech/Sci/R&D Officer | 01/01/2018 |
Elusys Therapeutics, Inc.
 Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | Chief Tech/Sci/R&D Officer | 01/04/2013 |
VaxInnate Corp.
 VaxInnate Corp. Pharmaceuticals: MajorHealth Technology VaxInnate Corp. develops novel, proprietary vaccines for infectious diseases. It engages in the development and production of vaccines for pandemic and seasonal influenza diseases. The firm's products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company was founded by Ruslan Medzhitov, Michael I. Sherman and Richard Flavell in 2002 and is headquartered in Cranbury, NJ. | Corporate Officer/Principal | 01/04/2016 |
Formation de Stephen Haworth
| University College London | Undergraduate Degree |
| UCL Medical School | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CORMEDIX INC. | Health Technology |
| XORTX THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | Health Technology |
VaxInnate Corp.
VaxInnate Corp. Pharmaceuticals: MajorHealth Technology VaxInnate Corp. develops novel, proprietary vaccines for infectious diseases. It engages in the development and production of vaccines for pandemic and seasonal influenza diseases. The firm's products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company was founded by Ruslan Medzhitov, Michael I. Sherman and Richard Flavell in 2002 and is headquartered in Cranbury, NJ. | Health Technology |
